Compare · JNJ vs MAIA
JNJ vs MAIA
Side-by-side comparison of Johnson & Johnson (JNJ) and MAIA Biotechnology Inc. (MAIA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and MAIA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $560.33B, about 6776.3x MAIA ($82.7M).
- Over the past year, JNJ is up 49.9% and MAIA is down 24.0% - JNJ leads by 73.9 points.
- MAIA has been more active in the news (13 items in the past 4 weeks vs 8 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 0 for MAIA).
- Company
- Johnson & Johnson
- MAIA Biotechnology Inc.
- Price
- $232.71+1.95%
- $1.36-8.72%
- Market cap
- $560.33B
- $82.7M
- 1M return
- +3.67%
- +0.74%
- 1Y return
- +49.92%
- -24.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2022
- News (4w)
- 8
- 13
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
Latest MAIA
- MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
- MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
- MAIA Biotechnology Announces Open Market Purchases by CEO and Director
- Chief Executive Officer Vitoc Vlad bought $100,886 worth of shares (72,700 units at $1.39), increasing direct ownership by 8% to 976,121 units (SEC Form 4)
- Director Smith Stan bought $100,200 worth of shares (75,000 units at $1.34) (SEC Form 4)
- Chief Scientific Officer Gryaznov Sergei bought $2,690 worth of shares (2,000 units at $1.34), increasing direct ownership by 4% to 46,511 units (SEC Form 4)
- SEC Form 4 filed by Chief Executive Officer Vitoc Vlad
- SEC Form 4 filed by Chief Scientific Officer Gryaznov Sergei
- SEC Form 4 filed by Head of Finance Himmelreich Jeffrey C
- MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology